Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

ABSTRACT:

Aim

Selexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy with endothelial receptor antagonists (ERAs) and PDE5is for Chinese PAH patients.

Methods and results

A single center retrospective study was performed on group 1 PAH patients (n = 68) initiating triple combination therapy with selexipag from 1 February 2020 to 31 August 2021 in Qilu Hospital of Shandong University (Shandong, China). Adolescents, children, and PAH patients with unrepaired congenital heart disease were excluded. The French pulmonary hypertension network (FPHN) non-invasive risk assessment, echocardiogram parame

SUBMITTER: Cui X 

PROVIDER: S-EPMC9530145 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature